**Pain Perception and Aspergillosis:

Why It Matters — and What Help Is Available**

Living with aspergillosis—whether Chronic Pulmonary Aspergillosis (CPA), Allergic Bronchopulmonary Aspergillosis (ABPA), Aspergillus bronchitis, or Severe Asthma with Fungal Sensitivity (SAFS)—can mean coping with symptoms that change day to day.
Pain, breathlessness, muscle aches, fatigue and joint discomfort are common. What many people don’t realise is that how the body perceives and processes pain plays a major role in how these symptoms feel — and how well they can be managed.

Understanding pain perception doesn’t mean your symptoms aren’t real. It means understanding why pain behaves the way it does in chronic illness — and how to gain more control.

1. Why pain perception matters in aspergillosis

Pain is produced by the nervous system, and is influenced by:

Inflammation in the lungs or sinuses
Muscle strain from coughing or altered breathing
Reduced fitness after flare-ups
Long-term corticosteroid use
Adrenal insufficiency
Stress, uncertainty, poor sleep, and emotional load

Pain is therefore a mix of bodily changes and how the brain interprets signals.
Both are real. Both deserve attention.

2. Muscle changes and increased sensitivity

People with aspergillosis may experience:

Weakened rib, back, and shoulder muscles
Reduced leg strength
Joint instability
Muscle fatigue leading to higher pain sensitivity

Everyday movements can feel more painful, and pain can worsen breathlessness. Many people fall into a cycle: flare-up → rest → muscle weakening → more pain → more breathlessness → more rest.

Understanding this cycle helps break it.

3. Stress, sleep and emotions influence pain

Pain becomes stronger when:

You are tired
You feel anxious, unsafe, or overwhelmed
Your symptoms are unpredictable
You have recently been in hospital
You are caring for someone who is unwell

This does not mean pain is psychological.
It means the nervous system becomes more alert, so signals feel louder.

Carers experience this too.

4. Why understanding pain helps you manage symptoms

Learning about pain perception helps you:

Pace activity wisely
Avoid panic when symptoms spike
Identify muscular vs inflammatory discomfort
Communicate clearly with clinicians
Reduce stress-driven symptom amplification
Prevent flare-ups by calming the nervous system

It’s not about ignoring symptoms — it’s about understanding them so you can respond safely and confidently.

5. NHS resources that can help

Below are useful links recommended across NHS pain services.

🔹 NHS self-help guidance on long-term pain

These pages offer practical advice on managing persistent pain, pacing, movement, and everyday strategies:

How to get NHS help for your pain
https://www.nhs.uk/live-well/pain/how-to-get-nhs-help-for-your-pain/

10 ways to reduce pain
https://www.nhs.uk/live-well/pain/10-ways-to-ease-pain/

These guides are suitable for people with chest pain, muscular pain, fatigue and inflammation linked to lung disease.

🔹 NHS Pain Management Programmes (PMP)

Many NHS Trusts run Pain Management Programmes. These provide a combination of physiotherapy, psychology, pacing education, flare-up planning, and medication review.

Examples of NHS PMP resources:

Royal Orthopaedic Hospital – PMP information
https://roh.nhs.uk/services-information/pain-management/pain-management-programme

Ashford & St Peter’s Hospitals – Pain Management Programme
https://www.ashfordstpeters.nhs.uk/the-pain-management-programme

Gloucestershire Hospitals – Pain Management Options
https://www.gloshospitals.nhs.uk/our-services/services-we-offer/pain-management-service/management-options-pain/

Speak to your GP or specialist team if you want a referral.

🔹 The Pain Toolkit (NHS-endorsed self-management booklet)

Widely used by NHS pain services and physiotherapy teams.

PDF:
https://www.nhsfife.org/media/c349s6xo/nhs-fife-pain-toolkit.pdf

This guide covers pacing, flare-up planning, problem-solving, emotional wellbeing and shared decision-making.

🔹 NHS Talking Therapies (for stress-related pain amplification)

If stress, anxiety or sleep disturbance are worsening your pain, NHS Talking Therapies services can help.

Find your local service here:
https://www.nhs.uk/service-search/mental-health/find-a-psychological-therapies-service/

These services support people with long-term physical conditions as well as mood and anxiety problems.

🔹 Physiotherapy & pulmonary rehabilitation

These services help with:

Breathing pattern retraining
Strengthening ribs, shoulders, back, hips, and knees
Improving stamina and reducing breathlessness
Reducing muscle pain and improving posture

Ask your GP, respiratory consultant, or specialist nurse for a referral.

6. What patients and carers can start today

✔ Notice pain patterns

Track fatigue, sleep, activity, stress, and symptoms.

✔ Practice pacing

Spread tasks through the day. Avoid pushing hard on “good days” — it often leads to flare-ups.

✔ Gentle strengthening

Even small daily exercises protect joints, support breathing and lower pain sensitivity.

✔ Reduce nervous-system overload

Breathing exercises, grounding, relaxation and mindfulness calm the system that amplifies pain.

✔ Seek help early

If pain changes or worries you, involve your GP or specialist team.

✔ Carers: protect your wellbeing

Carers benefit from pacing, strengthening and psychological support just as much as patients.

7. When to seek medical review

Contact your GP or specialist team urgently if you experience:

Sudden new chest pain
Pain with fever or coughing up blood
Pain that stops you breathing normally
Severe muscle weakness
Persistent flare-ups despite treatment
Symptoms suggesting adrenal problems

Pain in aspergillosis is real, but also manageable. With the right understanding and NHS-supported tools, you can reduce flare-ups, regain confidence, and improve daily life.

by GAtherton

⭐ Severe Asthma with Fungal Sensitisation (SAFS): The Hidden Burden Behind Difficult Asthma

Estimated prevalence: 15–30% of severe asthma patients show fungal sensitisation.

Severe Asthma with Fungal Sensitisation (SAFS) describes a group of patients with severe asthma who show sensitisation (allergy) to Aspergillus or other environmental moulds but do not meet criteria for ABPA. These patients often experience persistent inflammation, breathlessness, mucus production, and exacerbations that are not adequately controlled by standard asthma therapies.

Although SAFS is common in severe asthma clinics, it remains poorly recognised, frequently mislabelled, and rarely discussed in routine practice. Yet identifying SAFS is crucial because it opens the door to specific interventions — including antifungals or targeted biologics — that can improve symptoms and reduce hospital admissions.

⭐ How Common Is SAFS?

SAFS is more common than ABPA and CPA combined in asthma services.

Population	Estimated prevalence
Moderate asthma	~5%
Severe asthma	15–30%
Patients with frequent exacerbations	up to 40%
ABPA-negative patients with mucus plugging	high likelihood

Across the UK, this represents tens of thousands of people.

⭐ Why SAFS Is Missed

1. The diagnosis is not widely understood

Unlike ABPA or CPA, SAFS lacks:

universally agreed diagnostic criteria
clear imaging features
a single confirmatory test

This leads to variability in thinking and detection.

2. Symptoms mimic uncontrolled asthma

SAFS patients typically experience:

severe breathlessness
wheeze
mucus production
airway plugging
poor response to inhalers
frequent steroid courses

These appear indistinguishable from “difficult” or “type 2–high” asthma.

3. IgE and eosinophils may be normal

Unlike ABPA:

total IgE may be modest
Aspergillus IgE may be borderline
eosinophils may fluctuate, especially with steroids or biologics

Clinicians are often looking for very high IgE levels — but SAFS patients usually don’t show them.

4. Sputum and CT scans appear non-specific

Typical imaging:

mucus plugging
small-airway thickening
variable, patchy inflammation
bronchiectasis may or may not be present

Radiologists often report these changes as:

“consistent with asthma”
“post-infective”
“non-specific inflammatory pattern”

5. The fungal link is overlooked

Many clinicians are unfamiliar with:

the role of mould exposure
sensitisation thresholds
the overlap between environmental allergy and airway disease
when antifungals are appropriate

This leads to delays in recognising fungal-driven asthma.

⭐ Who Is at Highest Risk?

1. Severe asthma patients unresponsive to maximal inhaled treatment

Particularly those with:

frequent exacerbations
nocturnal symptoms
long-term steroid use
persistently low lung function
mucus plugging events

**2. Patients sensitised to Aspergillus or multiple moulds**

Positive skin tests or specific IgE indicate airway allergy that can drive symptoms.

3. Patients with damp or mould exposure at home or work

An important environmental factor often overlooked.

4. ABPA-negative asthma patients with mucus plugging

A large proportion of these patients fit the SAFS profile.

5. Those with co-existing bronchiectasis

Bronchiectasis amplifies the inflammatory response to fungal exposure.

⭐ Specialties That Need Greater Awareness

Severe asthma services & biologics clinics
(primary diagnostic opportunity)
General respiratory clinics
Primary care & urgent care
(patients seen frequently with “persistent asthma symptoms”)
Radiology
(important for identifying mucus plugging)
Allergy/Immunology
(mould sensitisation is central to diagnosis)
Environmental health teams
(exposure to mould and dampness often perpetuates symptoms)

The National Aspergillosis Centre can provide specialist input when diagnosis is unclear or response to treatment is suboptimal.

⭐ Red Flags Suggesting SAFS

1. Severe asthma poorly controlled despite maximal inhalers

Including biologics (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab).

**2. Sensitisation to Aspergillus fumigatus or multiple moulds**

3. Repeated mucus plugging episodes

(or “sticky mucus” symptoms)

4. More than 2–3 steroid-treated exacerbations per year

5. Asthma + bronchiectasis

Even mild bronchiectasis increases fungal risk.

6. Symptoms triggered by damp/mould exposure

7. Persistent airway inflammation despite correct inhaler technique

⭐ Misdiagnoses That Delay Recognition

“Difficult asthma”
“Brittle asthma”
“Post-viral inflammation”
“Poor adherence to inhalers”
“Asthma–COPD overlap”
“Psychogenic dyspnoea”
“Recurrent chest infections”

SAFS is a diagnosis hiding in these labels.

⭐ The Cost of Missed SAFS Diagnosis

For patients:

persistent symptoms
steroid dependence
increased risk of ABPA
progressive airway damage
hospital admissions
poor quality of life
possible career and lifestyle impact

For healthcare systems:

repeated A&E visits
asthma admissions
high biologic usage without adequate response
unnecessary antibiotics
escalating steroid toxicity
missed environmental interventions

⭐ Conclusion

SAFS is one of the most common — yet least recognised — fungal-related lung conditions. Although it lacks the dramatic imaging changes of ABPA or CPA, its impact on patients is profound.

Recognising mould sensitisation in severe asthma, understanding the role of fungal allergens, and considering targeted therapies can transform disease control. For complex cases or when the diagnosis is uncertain, referral to the National Aspergillosis Centre is recommended.

Early identification and appropriate treatment reduce steroid use, exacerbations, and long-term airway damage.

by GAtherton

⭐ Aspergillus Bronchitis: The Overlooked Condition Hiding in Plain Sight

Estimated prevalence 1–2% in bronchiectasis and chronic airway disease clinics.

Aspergillus Bronchitis (AB) is a chronic, symptomatic infection of the airways caused by Aspergillus species in people with underlying lung disease. It sits between simple colonisation and chronic pulmonary aspergillosis (CPA), and is frequently overlooked or mislabelled as “recurrent infection,” “post-viral symptoms,” or uncontrolled bronchiectasis.

Unlike CPA, Aspergillus Bronchitis does not require cavities or major structural destruction — which makes it both easier to miss and surprisingly common among people with chronic airway disease.

When recognised and treated (usually with antifungal therapy for several months), symptoms often improve significantly. But because awareness remains low, most patients cycle through unnecessary antibiotics, repeated exacerbations, and worsening airway disease before the real cause is identified.

⭐ What Exactly Is Aspergillus Bronchitis?

Aspergillus Bronchitis is defined by:

chronic productive cough
sputum growing Aspergillus species repeatedly
airway inflammation
symptoms lasting over 3 months
underlying airway disease (bronchiectasis, CF, COPD, prior TB, ABPA)
response to antifungal therapy

Unlike ABPA:

there is no allergic response,
IgE is usually normal,
eosinophils are normal or mildly elevated.

Unlike CPA:

there are no cavities on imaging,
IgG may be normal or only slightly elevated,
disease is confined to the airways, not lung tissue.

This places AB in a “grey zone” — often invisible unless specifically looked for.

⭐ Why Aspergillus Bronchitis Is Missed

1. Symptoms mimic common chronic airway disease

Typical AB symptoms include:

daily productive cough
worsening sputum thickness
breathlessness
fatigue
repeated “chest infections”
slow-to-clear mucus
crackles or wheeze

These resemble:

bronchiectasis exacerbations
COPD flare-ups
chronic infection with Pseudomonas or NTM
post-viral cough
uncontrolled asthma

Without fungal awareness, clinicians default to bacterial explanations.

2. Sputum grows multiple organisms — Aspergillus is dismissed

In bronchiectasis, sputum frequently grows:

Haemophilus
Pseudomonas
Staphylococcus
Streptococcus
NTM

When Aspergillus appears, it’s often labelled:

“colonisation”
“contaminant”
“not clinically relevant”

But repeated isolation with persistent symptoms is highly suggestive of AB.

3. IgE/IgG results may be normal

Many clinicians expect high IgE or IgG to “confirm Aspergillus disease.”
But in Aspergillus Bronchitis:

IgE is usually normal
IgG can be normal or borderline

This leads to false reassurance.

4. Radiology rarely shows overt features

CT scans in AB may show:

mucus plugging
mild bronchial wall thickening
small nodules
progression of bronchiectasis

But they do not show the cavities of CPA or classic features of ABPA.

Therefore radiologists often report scans as “no significant change” or “stable bronchiectasis.”

5. Antibiotics appear to help — temporarily

Patients often improve slightly with:

amoxicillin
doxycycline
macrolides
ciprofloxacin

This gives clinicians the impression of bacterial disease, but symptoms soon return.

6. Lack of awareness

Many specialists (even in respiratory clinics) are unaware that Aspergillus Bronchitis:

exists as a distinct clinical entity
can be disabling
responds to antifungals
predicts progression to CPA if untreated

This leads to significant diagnostic delay.

⭐ Who Is at Highest Risk?

1. Bronchiectasis

The largest risk group.
Aspergillus Bronchitis may account for 1–2% of all bronchiectasis patients, and up to 5–10% in severe or frequent exacerbator groups.

2. Cystic Fibrosis (CF)

These patients frequently grow Aspergillus but not all have ABPA — some have Aspergillus Bronchitis.

3. COPD and chronic productive cough

Especially those with:

frequent mucus plugging
repeated “infective exacerbations”
progressive sputum production

4. Post-TB airway damage

Chronic airway deformity, scarring, and bronchiectasis from old TB predispose to fungal infection.

5. Post-COVID structural disease

A new and growing risk group, especially after prolonged ICU ventilation.

6. ABPA patients

Some patients develop Aspergillus Bronchitis during steroid-dominated treatment or after stopping antifungals.

⭐ Which Specialities Need Greater Awareness?

Respiratory medicine
(especially bronchiectasis clinicians and severe asthma teams)
Infectious Diseases
(frequent respiratory presentations with chronic airway infection)
Radiology
(to recognise subtle but progressive airway changes)
Primary care
(“recurrent chest infection” or “persistent cough” patients)
Physiotherapy & airway clearance teams
(excessive sputum with fungal elements)
Cystic Fibrosis services

The National Aspergillosis Centre is the ideal referral destination when diagnosis is uncertain or symptoms persist despite typical management.

⭐ Red Flags Suggesting Aspergillus Bronchitis

1. Chronic (>3 months) productive cough + repeated Aspergillus in sputum

Even 2 positive sputums in the right clinical context should raise suspicion.

2. Bronchiectasis patient not improving on repeated antibiotics

3. Thick, tenacious mucus with black, grey, or brown plugs

4. Worsening CT bronchiectasis or mucus plugging

5. Absence of features typical for ABPA (normal IgE, no fleeting infiltrates)

6. Asthma or COPD patient with new persistent sputum

7. Partial response to antibiotics but rapid relapse

8. Unexplained fatigue and breathlessness in someone with airway disease

⭐ The Cost of Missed Aspergillus Bronchitis

If AB is not recognised early, consequences include:

repeated exacerbations
accelerating bronchiectasis
long-term airway damage
chronic inflammation
steroid overuse
unnecessary antibiotics
repeated hospitalisations
progression to CPA in some patients

For health systems, missed diagnosis leads to:

higher admission rates
inappropriate long-term antibiotic use
avoidable CT scans and investigations
greater long-term burden of CPA

But antifungal therapy — when appropriately used — can offer marked symptom improvement and reduce exacerbation frequency.

⭐ Conclusion

Aspergillus Bronchitis is a distinct, treatable form of chronic airway disease seen in people with bronchiectasis, asthma, COPD, CF, and post-TB lung damage. Yet lack of awareness means many patients are repeatedly misdiagnosed with bacterial infections or unexplained chronic cough.

Recognising red flags, reviewing sputum results carefully, and considering antifungal therapy can dramatically improve outcomes. Early referral to specialist centres such as the National Aspergillosis Centre is recommended for complex cases or uncertain diagnosis.

Early identification prevents airway deterioration — and reduces the likelihood of progression to CPA.

by GAtherton

⭐ Allergic Bronchopulmonary Aspergillosis (ABPA): Why Diagnosis Is Missed and Who Needs to Be More Aware

With estimated prevalence of 1–2% in asthma clinics and up to 10% in severe asthma services.

Allergic Bronchopulmonary Aspergillosis (ABPA) is a chronic immune reaction to Aspergillus that affects people with asthma or cystic fibrosis. It causes airway inflammation, mucus plugging, recurrent exacerbations, and bronchiectasis if untreated.

Despite being treatable, ABPA remains heavily underdiagnosed, even in countries with advanced respiratory services. Many people are told for years that they have “difficult asthma” or “recurrent chest infections,” only for ABPA to be diagnosed much later, often with significant lung damage already present.

The UK National Aspergillosis Centre (NAC) provides specialist expertise, yet only a small proportion of expected ABPA cases reach specialist review.

This article explains why ABPA is missed, which patients are at risk, which specialities need to be more alert, and the red flags that should prompt testing or referral.

⭐ How Common Is ABPA?

ABPA is more common than most clinicians realise:

Population	Estimated prevalence
General asthma	1–2%
Severe asthma clinics	3–10%
Cystic fibrosis	5–15%
Bronchiectasis (non-CF)	1–4%

Across the UK, this equates to an estimated 15,000–25,000 people living with ABPA — but only a small minority ever receive the correct diagnosis.

⭐ Why ABPA Is Often Missed

1. ABPA looks like “difficult asthma”

Typical symptoms — wheeze, cough, mucus, breathlessness — mimic:

severe asthma
eosinophilic asthma
uncontrolled asthma despite treatment

Patients may be repeatedly stepped up through inhalers, oral steroids, and biologics before ABPA is even considered.

2. Exacerbations are mistaken for infections

Many ABPA flare-ups are treated as:

pneumonia
viral infection
“chest infection”
post-viral asthma worsening

Without fungal-specific thinking, the diagnosis is rarely made.

3. IgE and eosinophils fluctuate

IgE is a cornerstone of ABPA diagnosis, but:

systemic steroids suppress IgE
biologics (benralizumab, mepolizumab, dupilumab) reduce eosinophils
flare-ups produce temporary spikes
baseline ranges vary between labs

Clinicians often overlook ABPA in patients on biologics because eosinophils are normal — despite the underlying fungal allergy still being active.

4. Radiology findings get mislabelled

ABPA causes:

mucus plugging
“tram lines” and bronchial thickening
fleeting infiltrates
upper lobe bronchiectasis

These are often:

labelled “infection”
attributed to asthma airway remodelling
not compared across time
missed on CT unless specifically looked for

5. Inconsistent awareness across specialities

Some clinicians are unfamiliar with:

ISHAM diagnostic criteria
interpreting IgE/IgG results
the relationship between asthma and fungal allergy
the overlap between ABPA and bronchiectasis

This leads to diagnostic delay or misdiagnosis.

6. ABPA evolves into chronic disease if untreated

Repeated inflammation → mucus plugging → bronchiectasis → fibrosis.
By the time a diagnosis is made, airway damage can be permanent.

⭐ Who Is at Highest Risk?

1. Asthma patients with repeated exacerbations

Especially those who:

fail maximal inhaler therapy
require multiple steroid courses
have sudden, dramatic mucus plugging events
experience episodic “flares” with no clear cause

2. Severe asthma clinic patients

Prevalence is up to 10%, especially those with:

high IgE
eosinophilia
sensitisation to multiple allergens
steroid dependence

3. Bronchiectasis patients

Bronchiectasis often coexists with ABPA and can worsen flares.

4. Patients with mucus plugging (“finger-in-glove” signs)

These striking CT appearances strongly suggest ABPA but are often misattributed to infection.

5. People with CF (Cystic Fibrosis)

5–15% develop ABPA at some stage.

⭐ Which Specialities Need Greater Awareness?

Severe asthma services & biologics clinics
(highest yield group for ABPA detection)
Respiratory medicine
(diagnosis often falls here but is highly variable)
General practice
(sees frequent “exacerbations”)
Emergency departments & acute medical units
(manage acute mucus plugging, chest tightness)
Paediatric respiratory medicine
(early recognition prevents chronic damage)
Cystic Fibrosis services
Radiology
(fleeting infiltrates and mucus plugging often give the earliest clues)

The National Aspergillosis Centre should be the referral point for complex or uncertain cases.

⭐ Red Flags Suggesting ABPA

1. Asthma with repeated, unexplained exacerbations

Especially if poorly responsive to normal treatment.

2. High total IgE (>500–1000 IU/mL)

Or rising IgE over time.

3. Eosinophilia (unless suppressed by treatment)

4. Positive Aspergillus sensitisation

(Skin prick test or specific IgE)

5. Bronchiectasis, particularly central or upper lobe

6. Fleeting pulmonary infiltrates

7. Mucus plugging on CT (“finger-in-glove” appearance)

8. ABPA flare triggered by stopping antifungals

9. Asthma + Aspergillus in sputum

⭐ The Cost of Missed ABPA Diagnosis

Failure to diagnose ABPA leads to:

progressive airway damage
permanent bronchiectasis
steroid dependence
hospital admissions
repeated infections
respiratory failure in advanced stages
reduced quality of life
avoidable healthcare expenditure

Delayed diagnosis increases the risk of progression to CPA, a far more serious chronic fungal infection requiring long-term antifungal therapy.

Early recognition, correct treatment, and referral to specialist centres like the National Aspergillosis Centre dramatically improve long-term outcomes.

⭐ Conclusion

ABPA is not rare — especially within severe asthma clinics, bronchiectasis services, and CF units. Yet it remains significantly underdiagnosed because its symptoms mirror those of common respiratory conditions, and because key investigations like IgE, IgG, and CT interpretation are inconsistently used.

A structured approach — recognising red flags, performing appropriate testing, and referring complex cases to the National Aspergillosis Centre — can reduce the burden of avoidable airway damage and improve the lives of thousands of patients.

by GAtherton

⭐ Chronic Pulmonary Aspergillosis: Why Diagnosis Is Missed and Who Needs to Be More Aware

With estimated prevalence of 3–4 cases per 100,000 population, and far higher rates in high-risk groups.

Chronic Pulmonary Aspergillosis (CPA) is a slowly progressive fungal lung disease affecting an estimated 3–4 per 100,000 people in the UK, with higher estimates in global settings with greater TB prevalence. Despite this, many clinicians will go through entire careers without confidently recognising it — not because it is extremely rare, but because it almost always hides inside other long-term lung diseases.

The UK is unusual in having a nationally commissioned specialist service — the National Aspergillosis Centre (NAC), based at Wythenshawe Hospital, Manchester — offering funded diagnostics, multidisciplinary review, and long-term antifungal management. But only a fraction of expected CPA cases are ever referred. Most are simply never diagnosed.

This article explains why diagnoses are missed, who is at highest risk, which specialities need to be more alert, and the red flags that should trigger testing or referral.

⭐ How Common Is CPA? The Numbers Behind the Problem

The UK prevalence is estimated at 3–4 per 100,000 people — approximately 2,000–2,500 people with CPA at any given time.

But the risk is far higher in specific groups:

Risk Group	Estimated CPA prevalence
Post-TB lung disease	6–10% in those with residual cavities
Severe COPD (GOLD III–IV)	1–3%
Bronchiectasis	1–3%
NTM disease	3–10%
Sarcoidosis with fibrosis	1–2%
Immunosuppression (steroids/biologics)	Unknown, but rising

Using these figures, the true UK caseload could exceed 4,000–6,000 individuals, yet NAC receives ~500–1,000 referrals, highlighting a large diagnostic gap.

⭐ Why CPA Is So Often Missed

1. Symptoms mimic common chronic lung diseases

CPA presents with:

Persistent cough
Breathlessness
Fatigue
Weight loss
Recurrent “chest infections”
Haemoptysis

These overlap almost perfectly with:

COPD
bronchiectasis
post-TB changes
long COVID
NTM infection
repeatedly “slow to clear” pneumonia

Because symptoms are non-specific, clinicians rarely think fungal.

2. Interpretation of imaging is inconsistent

CPA shows:

one or more cavities
pleural thickening
nodules
progressive changes over months
fungal balls

Common reporting pitfalls:

labelled “post-infective scarring”
misinterpreted as malignancy
seen but not compared longitudinally
incidental CT findings not acted upon

Radiology is one of the biggest missed opportunities for early detection.

3. IgG testing is not routinely requested

Aspergillus IgG is the key diagnostic biomarker — but it is:

often confused with IgE
not available in some hospitals
omitted from workups for recurrent infection
unfamiliar to non-respiratory clinicians

Without IgG, CPA is rarely diagnosed.

4. Short-term improvement with antibiotics is misleading

Patients with CPA may temporarily feel better after:

broad-spectrum antibiotics
steroids
physiotherapy

This transient improvement creates false reassurance.

5. CPA spans multiple specialisms — and no one owns it

Diagnosis requires combined expertise across:

respiratory medicine
infectious diseases
radiology
microbiology
immunology

When no one speciality takes responsibility, patients get lost.

⭐ Which Patients Are at High Risk?

CPA almost always develops on a background of existing lung damage.

1. Post-TB lung disease (PTLD)

Globally the largest CPA population.
Residual cavities are the strongest predictor.

Specialities needing awareness:

TB teams
ID physicians
Radiologists
Community TB nurses
Public health TB programmes

2. COPD (especially severe / emphysema)

Millions of people are potentially at risk.
Recurrent infections + bullae/cavities = fertile ground for CPA.

Specialities:

COPD clinics
Pulmonary rehab
Acute medicine (frequent admissions)

3. Bronchiectasis

Damaged airways enable persistent Aspergillus colonisation and inflammation.

Specialities:

Bronchiectasis MDTs
Severe asthma & NTM clinics
Respiratory physiotherapy

4. Sarcoidosis and ILD

Fibrosis and traction bronchiectasis develop cavities over time.

5. Post-COVID or post-influenza structural disease

Emerging risk group, especially in patients with:

ventilatory lung injury
persistent CT abnormalities
chronic steroid exposure

6. Chronic steroid or immunomodulator use

While invasive aspergillosis is linked to profound immunosuppression, CPA often affects those with milder, chronic immune dysfunction:

systemic steroids
high-dose inhaled steroids
biologics affecting eosinophils
poorly controlled diabetes
chronic kidney disease
malnutrition

⭐ Which Specialities Need to Be More Alert?

Respiratory Medicine – primary detection, but awareness varies greatly
Infectious Diseases – especially post-TB and persistent infection clinics
Radiology – key to spotting early changes
Primary Care – sees patients repeatedly with “ongoing chest infections”
Emergency & acute medicine – haemoptysis presentations
Bronchiectasis and NTM services – strong overlap
Severe asthma and biologics teams – ABPA → CPA evolution
TB clinics – highest prevalence globally, often least recognised

The National Aspergillosis Centre should be the referral point for any complex or uncertain case.

⭐ Red Flags: When to Suspect CPA

1. Cavities on CT (thin-, thick-walled, evolving, or multiple)

Especially with pleural thickening.

2. Haemoptysis

CPA is one of the most common causes of haemoptysis in people with cavities.

3. Symptoms lasting >3 months

Chronic cough, fatigue, weight loss, breathlessness.

4. “Recurrent infections” that never fully resolve

5. Post-TB patient with any new or worsening symptoms

6. Bronchiectasis patient with new cavity or Aspergillus culture

7. High or rising Aspergillus IgG

8. ABPA patient who deteriorates off antifungals

⭐ The Cost of Missed Diagnoses

When CPA is not recognised early, the consequences are severe:

irreversible lung damage
repeated hospitalisations
emergency haemoptysis events
prolonged antifungal therapy with more toxicity
reduced quality of life
avoidable deaths

For systems like the NHS, late diagnosis increases costs:

unplanned admissions
repeated CT imaging
prolonged antibiotics
intensive care during haemoptysis
complex surgery (lobectomy/pneumonectomy)

Early referral to specialist centres like the National Aspergillosis Centre prevents many of these harms.

⭐ Conclusion

CPA is not rare within the populations most likely to develop it.
Missed diagnoses are common, predictable, and preventable.

By increasing awareness across Respiratory, Infectious Diseases, Radiology, Primary Care, TB services, and severe asthma pathways — and by using simple tools such as Aspergillus IgG and careful CT interpretation — clinicians can dramatically reduce the diagnostic delay that damages lungs, quality of life, and survival.

The UK is fortunate to have the National Aspergillosis Centre as a nationally commissioned referral service. Recognising CPA early and referring appropriately has the power to save lives, reduce system costs, and improve long-term outcomes.

by GAtherton

Why do some people with aspergillosis lose weight on the hips and thighs, but gain around the waist?

Many people living with aspergillosis, bronchiectasis or ABPA notice their body shape changing as they get older — especially after 60.
A very common pattern is:

Thinner hips and legs
More weight around the waist or tummy

This can feel confusing, but there are clear reasons why it happens.

1. Chronic lung conditions make it harder to keep leg and hip muscle

When you live with a long-term lung condition, you often have:

Breathlessness
Fatigue
Repeated chest infections
Less ability to walk long distances or climb stairs

Because the legs work harder than any other muscles, they are the first to lose strength and size when activity drops.
This is why many people notice:

Slimmer thighs
Smaller hips
Feeling weaker when getting out of a chair

This is partly due to age, but it happens faster in people with chronic lung disease.

2. Steroids can move weight from the limbs to the waist

Many aspergillosis patients have had:

Several courses of prednisolone over the years
High-dose inhaled steroids
Hydrocortisone replacement for adrenal problems

Even short or occasional courses can cause fat redistribution, where:

Fat and muscle reduce in the arms, hips and legs
More fat settles around the stomach area
The centre of the body becomes rounder even if the overall weight hasn’t changed much

This effect can continue long after stopping steroids.

3. Ageing naturally shifts fat towards the waist

After about age 60, the body changes how it stores fat:

Less around the hips and thighs
More around the waist
More “internal” fat around organs (visceral fat)

This happens to everyone, but can be more noticeable in people with aspergillosis because illness already reduces leg muscle.

4. You can lose muscle even if weight on the scales stays the same

Many patients say,
“I feel thinner and thicker at the same time.”

That’s because:

Muscle in the legs may be lost
Fat around the waist may increase
The total body weight doesn’t always change much

This is a normal pattern in long-term lung disease.

5. Illness, flare-ups, infections and poor appetite add to this

During flare-ups or infections, it’s common to:

Eat less
Feel exhausted
Lose muscle faster
Keep or gain tummy fat

The body burns muscle first when unwell, not fat — especially not tummy fat.

Is this dangerous?

Not usually on its own — but it does mean:

Legs may feel weaker
Balance and stamina can reduce
It may be harder to stay active

Strength and gentle exercise (within your limits) can help rebuild some leg muscle.

If weight changes are sudden or unexplained, they should always be discussed with your GP or specialist.

In summary

This body-shape change is very common in people with aspergillosis over 60.
It’s caused by a combination of:

Reduced activity due to breathlessness
Loss of leg and hip muscle
Steroid effects on fat distribution
Natural age-related changes
Appetite changes during illness

It doesn’t mean you’re doing anything wrong — it’s simply a pattern seen in many people with long-term lung disease.

by GAtherton

Physiotherapy and Aspergillosis: Why It Matters

Physiotherapy is an important part of care for many people with aspergillosis, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), aspergillus bronchitis, and severe asthma with fungal sensitisation (SAFS).
It doesn’t diagnose the disease on its own, but physiotherapists play a key role in detecting symptoms, collecting good sputum samples, and helping patients stay stable.

1. How Physiotherapy Helps With Diagnosis

🔍 A. Spotting patterns of sputum, breathlessness, and airway clearance problems

Respiratory physiotherapists often notice:

Thick, sticky mucus that is difficult to clear
Recurrent phlegm plugs
Wheeze, crackles, or airflow changes
Reduced ability to clear secretions after infection
These patterns can be early clues pointing toward ABPA, aspergillus bronchitis, or bronchiectasis linked to Aspergillus.

🔍 B. Supporting high-quality sputum collection

A good sputum sample is essential for:

Fungal culture
PCR
Galactomannan tests
Antibiotic/antifungal susceptibility testing

Techniques like huff coughing, breathing control, postural drainage, or using devices such as Acapella or Aerobika help ensure the sample comes from deep in the lungs, not just saliva.

🔍 C. Identifying airway collapsibility or dysfunctional breathing

Physiotherapists can pick up:

Tracheobronchomalacia
Inducible laryngeal obstruction
Breathing pattern disorder
These are often overlooked and can mimic or worsen aspergillosis symptoms.

If a physio notices these features, they feed findings back to the medical team, supporting a faster, more accurate diagnosis.

2. How Physiotherapy Helps With Treatment

🫁 A. Airway clearance

One of the biggest challenges in aspergillosis—especially ABPA, CPA, and bronchiectasis—is mucus.
Physiotherapy helps patients learn techniques to keep the lungs clear:

Active Cycle of Breathing Techniques (ACBT)
Huffing
Directed huff / forced expiration technique
Gravity-assisted drainage
Oscillating PEP devices (Acapella/Aerobika)
Autogenic drainage
Saline nebulisers to thin mucus

Keeping the airways clear:

Reduces cough and breathlessness
Helps antifungal treatment reach affected areas
Lowers risk of infection and flare-ups
Improves quality of life

💨 B. Managing breathlessness and fatigue

Physiotherapists teach:

Breathing control
Pacing techniques
Positions of ease
Diaphragmatic breathing
Inspiratory muscle training (if appropriate)

This is especially valuable for patients with:

ABPA flare-ups
CPA with reduced lung capacity
COPD or asthma overlap
Deconditioning after illness

🏃 C. Exercise, strength, and rehabilitation

Long-term aspergillosis can reduce fitness due to:

Repeated infections
Inflammation
Steroid side-effects
Time spent resting

Physios provide personalised rehab plans to rebuild:

Strength
Endurance
Balance
Activity levels
Confidence

🧠 D. Managing the “vicious cycle” of breathlessness and anxiety

Breathlessness naturally triggers anxiety, which then worsens breathlessness.
Physiotherapists help break this cycle through:

Breathing retraining
Relaxation strategies
Education on pacing and control

This also reduces the number of A&E visits for “flare-ups” that are actually driven by breathlessness-anxiety spirals.

3. Supporting Long-Term Stability

Regular physiotherapy follow-up helps patients:

Spot flare-ups early
Adjust airway clearance routines
Stay active despite chronic illness
Prevent hospital admissions
Maintain independence

For many patients with aspergillosis, physio becomes a key part of long-term disease management, just like antifungals, inhalers, and specialist review.

4. When Should Patients See a Physiotherapist?

Physiotherapy is particularly helpful if you have:

ABPA with repeated mucus plugging
CPA with sputum, breathlessness, or reduced activity
Bronchiectasis
Frequent chest infections
Difficulty producing sputum for testing
Breathing pattern disorder
Muscle weakness from steroids or long illness
Unexplained breathlessness
Tracheal or airway collapsibility

Summary

Physiotherapy is not just an “add-on” to aspergillosis care—it is a core part of both diagnosis and treatment.
Physiotherapists help:

Identify airway issues
Support accurate testing
Improve breathing control
Clear mucus
Build strength and stamina
Stabilise long-term disease

This combination leads to better outcomes, fewer infections, and a better quality of life.

by GAtherton

⭐ Key Themes This Week (weekly updates Early December 2025: week 49)

1. CPA as an Immune Dysfunction Syndrome – Not Just Structural Lung Disease

Two papers (Janssen et al., Aegerter et al.) add weight to the concept that chronic pulmonary aspergillosis (CPA) is driven not only by underlying lung architecture but by defects in host immunity, including:

Impaired IFN-γ production
Inflammatory effects of Charcot–Leyden crystals (CLC) in mucus
These findings support future directions in host-directed therapy and targeted immunological profiling.

2. Improved Diagnostics: Molecular, Imaging & Bronchoscopy

Significant focus this week on diagnostic innovation:

PCR and multi-target molecular testing in cancer patients (Rickerts et al.)
Radiolabelled siderophore imaging capable of identifying infected regions early (Dvorakova Bendova et al.)
Bronchoscopic signatures of tracheobronchial aspergillosis (Tapia Barredo et al.)
Together, these highlight a shift toward rapid, non-invasive, high-sensitivity diagnostics for invasive and chronic disease.

3. Global Variation in Antifungal Resistance

The Indian susceptibility study (Nikhil et al.) reinforces the strong geographic variability in Aspergillus susceptibility patterns. This may influence both local empiric practice and global surveillance needs.

4. Increasing Recognition of ABPA Beyond Classic Asthma

ABPA continues to be diagnosed in wider groups, including asthma–COPD overlap (Wang et al.), eosinophilic diseases, and cases overlapping with autoimmune conditions (Chakravarty et al.).
This implies:

A need for broader screening,
Awareness that ABPA can mimic inflammatory or autoimmune disease.

5. High ICU Burden – Viral/Fungal Interactions Persist

Papers on influenza-associated aspergillosis (Cabug et al.) and severe ICU presentations (multiple case reports) reflect continuing evidence that viral infections—especially influenza—significantly increase risk for IA hospitalization and mortality.

6. Uncommon Presentations & Rare Pathogens

Reports of hydropneumothorax, prosthetic joint infection (A. penicillioides), endophthalmitis, and DiGeorge-associated aspergillosis show the wide clinical spectrum and the need for clinical suspicion—especially in immunocompromised hosts.

📚 Detailed Summaries of This Week’s Publications

1. Clinical Case Reports & Presentations

Tolosa-Hunt Syndrome Lookalikes Including Orbital Aspergillosis

Bommala S et al. | Cureus | 1 Dec 2025
DOI: https://doi.org/10.7759/cureus.74532
This case of painful ophthalmoplegia outlines key mimics of Tolosa-Hunt syndrome, including orbital aspergillosis, carotid–cavernous fistula, Burkitt lymphoma metastasis, and Miller-Fisher syndrome.
Key takeaway: Orbital aspergillosis remains an important differential in patients with severe unilateral headache and ocular motor palsies.

**Survival from A. terreus IPA on Sequential VA–VV ECMO**

Ordaz EGM | Research Square (preprint) | 28 Nov 2025
DOI (preprint): https://doi.org/10.21203/rs.3.rs-1127632/v1
Describes a critically ill patient requiring sequential extracorporeal support who survived proven invasive pulmonary aspergillosis (A. terreus).
Key takeaway: ECMO does not eliminate diagnostic challenges; persistent bronchoscopy and culture remain essential.

Recurrent Hydropneumothorax in CPA

Tang C et al. | BMJ Case Reports | 26 Nov 2025
DOI: https://doi.org/10.1136/bcr-2024-268568
An immunocompetent patient developed recurrent hydropneumothorax ultimately linked to chronic cavitary pulmonary aspergillosis.
Key takeaway: CPA may present with pleural complications such as hydropneumothorax, not only cavities or haemoptysis.

Bronchoscopic Appearance of Tracheobronchial Aspergillosis

Tapia Barredo L et al. | Med Intensiva | 27 Nov 2025
DOI: https://doi.org/10.1016/j.medin.2025.10.001
Provides macroscopic descriptions of TBA during bronchoscopy.
Key takeaway: Helps clinicians recognise TBA early, especially in ventilated or immunosuppressed patients.

Prosthetic Knee Joint Infection by Aspergillus penicillioides

Nakano H et al. | BMC Infect Dis | 24 Nov 2025
DOI: https://doi.org/10.1186/s12879-025-1645-8
A very rare cause of prosthetic joint infection, requiring prolonged antifungal therapy.
Key takeaway: Rare species can cause deep tissue infections; species identification and susceptibility testing essential.

2. Epidemiology & Burden

ABPA in Asthma–COPD Overlap (China)

Wang W et al. | Respiratory Medicine | 27 Nov 2025
DOI: https://doi.org/10.1016/j.rmed.2025.108547
Reports rates of ABPA in adults with both asthma and COPD.
Key takeaway: ACO populations may have significantly higher ABPA prevalence than asthma alone, suggesting under-recognition.

Aspergillosis-Related Mortality in the United States

Walsh TJ et al. | Clinical Infectious Diseases | 24 Nov 2025
DOI: https://doi.org/10.1093/cid/ciaf653
Analysis of national death certificates shows invasive aspergillosis frequently listed as a primary cause of death.
Key takeaway: High mortality persists, reinforcing the importance of early detection and aggressive management.

3. Diagnostics & Imaging

Molecular Diagnostics in Cancer Patients with Suspected IA

Rickerts V et al. | J Clin Microbiol | 26 Nov 2025
DOI: https://doi.org/10.1128/jcm.01201-25
Evaluates multi-target PCR and antigen testing in BAL and serum.
Key takeaway: Supports wider adoption of rapid molecular diagnostics in high-risk oncology settings.

Radiolabelled Siderophores for Aspergillosis Imaging

Dvorakova Bendova K et al. | npj Imaging | 26 Nov 2025
DOI: https://doi.org/10.1038/s44304-025-00163-y
Rat studies show radiolabelled siderophores accumulate specifically in infected lung tissue.
Key takeaway: Potential groundbreaking tool for early non-invasive localisation of IA lesions.

4. Immunology & Pathogenesis

Defective IFN-γ Responses in CPA

Janssen NAF et al. | J Infect Dis | 29 Nov 2025
DOI: https://doi.org/10.1093/infdis/jiaf596
CPA patients demonstrate impaired interferon-gamma production.
Key takeaway: Suggests a consistent, measurable immune defect—opening doors for immunomodulatory therapies.

Charcot–Leyden Crystals in ABPA (Preprint)

Aegerter H et al. | medRxiv | 27 Nov 2025
DOI: https://doi.org/10.1101/2025.11.27.1126628
Shows that CLCs are present in ABPA sputum and directly promote airway inflammation.
Key takeaway: CLCs are not passive by-products—they drive pathology, especially in mucus-plugging conditions.

IL-18Rα Expression and Viral–Fungal Interactions

Cabug AF et al. | Nat Commun | 24 Nov 2025
DOI: https://doi.org/10.1038/s41467-025-50342-1
Demonstrates how IL-18Rα high-expressing T cells influence severe viral disease and contribute to influenza-associated pulmonary aspergillosis.
Key takeaway: Connects viral immunopathology with susceptibility to IAPA.

5. Treatment & Resistance

Antifungal Susceptibility in Eastern India

Nikhil A et al. | MicrobiologyOpen | 1 Dec 2025
DOI: https://doi.org/10.1002/mbo3.70136
Includes 431 CPA isolates, plus ABPA and other pulmonary forms.
Key takeaway: Confirms significant regional variation in azole susceptibility—important for stewardship.

Off-label Use of Novel Antimicrobials

Retamar-Gentil P et al. | JAC-AMR | 24 Nov 2025
DOI: https://doi.org/10.1093/jacamr/dlaf184
Provides expert consensus on off-label antifungal use, including isavuconazole in refractory cases.
Key takeaway: Practical guidance for difficult-to-treat IA and mucormycosis.

IMI in Children – Progress & Barriers

Yeoh DK et al. | Clin Microbiol Infect | 27 Nov 2025
DOI: https://doi.org/10.1016/j.cmi.2025.11.015
Comprehensive review of invasive mould infections in paediatrics.
Key takeaway: Diagnostics remain limited; clinical suspicion remains essential.

6. Other Notable Reports

HES Mimicking ABPA/EGPA

Chakravarty K et al. | Oxf Med Case Rep | 26 Nov 2025
DOI: https://doi.org/10.1093/omcr/omaf238
Key takeaway: Eosinophilic disorders can closely mimic ABPA, requiring careful differential diagnosis.

Traumatic Fungal Endophthalmitis

Farnan R et al. | BMC Ophthalmol | 25 Nov 2025
DOI: https://doi.org/10.1186/s12886-025-0661-5
Key takeaway: Aspergillus and Fusarium remain major causes of post-traumatic fungal endophthalmitis.

22q11.2 Deletion Syndrome & Disseminated Aspergillosis

Liebling E et al. | Orphanet J Rare Dis | 24 Nov 2025
DOI: https://doi.org/10.1186/s13023-025-04041-x
Key takeaway: Severe immunodeficiency predisposes to disseminated fungal infection; vigilance required.

by GAtherton

Advisory note: Preventing shingles for people with aspergillosis (ABPA, CPA, SAFS, severe asthma)

People living with aspergillosis often have additional factors that can increase the chance of shingles. The good news is that most of the risk can be reduced with vaccination, good overall health management, and early treatment of flares.

⭐ 1. Why people with aspergillosis may be at higher risk

Several common parts of ABPA/CPA management can slightly increase the chance of shingles:

🔸 Long-term or repeated oral steroids

(e.g., prednisolone, methylprednisolone, hydrocortisone)

Steroids suppress parts of the immune system, making it easier for the varicella-zoster virus to reactivate.
Even short courses can temporarily raise the risk.

🔸 Biologic treatments

(e.g., omalizumab, benralizumab, dupilumab, tezepelumab)

Biologics do not massively weaken immunity, but they do adjust key immune pathways and may slightly increase susceptibility to viral reactivation in some people.
For most patients the risk is small — but it still supports the case for vaccination.

🔸 Long-term lung disease (CPA, bronchiectasis, ABPA)

Chronic inflammation and repeated infections place extra strain on the immune system.
Many patients also experience fatigue and poor sleep, which contributes.

🔸 Other health factors

Older age (risk rises sharply after 50)
Diabetes
Nutrient deficiencies (low vitamin D, B12, folate, iron)
Recent infection, hospitalisation or surgery
High stress levels or poor sleep

⭐ 2. Vaccination — your strongest protection

The UK uses Shingrix, a non-live vaccine, safe for nearly all patients with aspergillosis, including those on:

✓ Long-term steroids
✓ Antifungals (itraconazole, voriconazole, posaconazole, isavuconazole)
✓ Biologics
✓ Immunosuppressants
✓ Long-term antibiotics for bronchiectasis

How long does protection last?

Very high protection for at least 10 years
~80–85% protection still present at year 10
No booster currently recommended

If you're over 50, or at higher risk due to medications or immune status, you are usually eligible.

⭐ 3. What else you can do

🔸 Keep inflammation under control

Flares of ABPA, CPA progression, chest infections or sinusitis all place extra strain on the immune system.
Early treatment helps reduce shingles risk.

🔸 Protect your general immunity

Good sleep
Pacing and avoiding exhaustion
Managing stress where possible
Eating routinely and correcting low nutrients (vitamin D, B12, folate, iron)

🔸 Keep up with preventive routines

Airway clearance
Prompt treatment of infections
Attending monitoring appointments
Keeping antifungal or biologic treatment stable where possible

⭐ 4. Know the early warning signs

Early treatment with antivirals works best if started within 72 hours.

Pain, tingling, burning or heightened sensitivity in a band or patch
Followed by a rash or blisters on one side of the body or face

Seek GP/urgent care the same day.

⭐ Summary for aspergillosis patients

You may be at slightly higher risk of shingles if you:

Take oral steroids
Use biologic injections
Have CPA, ABPA, bronchiectasis or long-term lung inflammation
Have low immunity, poor sleep, or ongoing infections

You can significantly reduce your risk by:

Getting the Shingrix vaccine if eligible
Managing flares and infections promptly
Supporting your immune system through sleep, pacing and nutrition
Acting early if symptoms of shingles appear

by GAtherton

COVID Vaccines: Yes, There Is Some Risk — But COVID Infection Causes Far More Harm

People living with aspergillosis, CPA, ABPA, bronchiectasis, asthma or sarcoidosis often feel understandably anxious about vaccination.
Concerns about myocarditis, side effects, and frightening stories online are completely normal.

But when you compare the risks of the vaccine with the risks of COVID infection, a clear picture emerges:

⚠️ The vaccine carries some risk

🚨 COVID infection carries far, far more risk — and affects almost everyone

This article explains that difference clearly and honestly.

**1. COVID vaccines can cause harm — but this is rare**

No medical treatment is risk-free.
A very small number of people experience:

Fever
Fatigue
Headache
Swollen glands
Sore arm
Mild myocarditis (usually short-lived, rare, and mostly in young men)

Serious reactions such as hospitalisation or anaphylaxis are extremely rare — roughly 1–2 cases per million doses.

We should acknowledge this openly.

2. Almost everyone has had COVID in the last five years

Across the UK and most of the world, over 90% of adults now show antibodies from a past COVID infection, even if they didn’t realise they had it.

Many infections felt like a cold or passed unnoticed, but the body still experienced real risks:

heart inflammation
blood clots
lung inflammation
long-term fatigue
worsening of existing lung disease

Many people have had COVID more than once, and the risks increase with repeated infections.

So when we compare vaccine risk with infection risk, we’re not discussing a rare scenario — we are talking about something nearly everyone has already experienced, often multiple times.

3. COVID vaccines have prevented millions of hospitalisations and deaths

Global studies estimate that:

In the first year alone, COVID vaccines prevented around 19 million deaths worldwide.
WHO Europe reports more than 1.4 million lives saved in Europe alone.
A wider analysis suggests vaccines prevented over half of all potential hospitalisations and severe outcomes across many countries.

A simple way to think about it:

For every serious vaccine reaction, the vaccine prevents tens of thousands of hospitalisations and deaths.

This benefit is especially important for people with:

chronic lung disease
aspergillosis
bronchiectasis
asthma
immune suppression
long-term steroid use

For these groups, the protective effect of vaccination is greater than average, because COVID complications are more dangerous.

4. COVID infection causes far more harm than the vaccine

This is the crucial point.

COVID infection is 30–100 times more likely to cause myocarditis than the vaccine.

And infection-related myocarditis is:

more severe
more likely to require hospital care
more likely to leave long-term effects

COVID infection also increases the risk of:

blood clots
heart attacks
strokes
lung scarring
long COVID
ICU admission
worsening of asthma, ABPA, CPA and bronchiectasis

And the risk of death from infection is hundreds of times higher than the risk from vaccination.

5. Why scare stories feel louder than scientific facts

Scary individual stories spread quickly online.
But they are rare.

What we don’t see in the same dramatic way:

“Thousands of vulnerable patients avoided severe illness because they were vaccinated.”
“Vaccination prevented hospital admissions this week.”
“Most myocarditis cases after vaccination recover fully within days.”

Positive outcomes never go viral — but they happen constantly.

6. What this means for people with aspergillosis

COVID infection can:

trigger ABPA flares
worsen CPA cavities
increase mucus blockage
increase breathlessness
raise the risk of secondary fungal infections
accelerate lung damage
lead to hospitalisation

Vaccination significantly reduces all of these risks.

For most people with aspergillosis, vaccination is far safer than repeated COVID infections.

7. A supportive message for anyone still unsure

“It's true the vaccine carries some risk — all medicines do.
But COVID infection carries far, far more risk, and nearly everyone has had it at least once already.
Vaccination is the option that best protects your heart, your lungs, and your long-term health.”

by GAtherton